CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $17.40 million for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-12-27 was $0.00.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-09-27 was $17.40M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2025 was $17.40M, a 8.07% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2024 was $16.10M.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|---|---|---|
| 2025-12-27 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $17.40M derived: sum of 2 quarters · filed 2026-02-18 | $17.40M 10-K · filed 2026-02-18 | |
| 2025-09-27 | $17.40M 10-Q · filed 2025-11-05 | $17.40M 10-Q · filed 2025-11-05 | ||
| 2024-12-28 | $16.10M 10-K · filed 2026-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |